Community Financial Services Group LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 0.6% during the 4th quarter, HoldingsChannel reports. The fund owned 216,884 shares of the biopharmaceutical company’s stock after acquiring an additional 1,375 shares during the quarter. Pfizer accounts for approximately 3.0% of Community Financial Services Group LLC’s investment portfolio, making the stock its 9th largest holding. Community Financial Services Group LLC’s holdings in Pfizer were worth $7,856,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in PFE. Beach Investment Management LLC. purchased a new position in shares of Pfizer during the 2nd quarter valued at about $5,214,000. Northpointe Capital LLC raised its holdings in shares of Pfizer by 4.6% during the 2nd quarter. Northpointe Capital LLC now owns 145,544 shares of the biopharmaceutical company’s stock valued at $4,889,000 after buying an additional 6,374 shares in the last quarter. Horan Capital Advisors LLC. raised its holdings in shares of Pfizer by 30.3% during the 2nd quarter. Horan Capital Advisors LLC. now owns 8,695 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 2,023 shares in the last quarter. LLBH Private Wealth Management LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at about $971,000. Finally, Alps Advisors Inc. raised its holdings in shares of Pfizer by 3.6% during the 2nd quarter. Alps Advisors Inc. now owns 1,452,222 shares of the biopharmaceutical company’s stock valued at $48,780,000 after buying an additional 50,200 shares in the last quarter. 71.41% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages recently weighed in on PFE. BMO Capital Markets set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, March 6th. Jefferies Group set a $39.00 price objective on Pfizer and gave the company a “hold” rating in a report on Monday, February 26th. Barclays raised their price target on Pfizer from $38.00 to $41.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 31st. Credit Suisse Group raised their price target on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 31st. Finally, Leerink Swann raised their price target on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. Pfizer has an average rating of “Hold” and a consensus target price of $39.40.
In other news, insider Mikael Dolsten sold 69,699 shares of Pfizer stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $36.59, for a total value of $2,550,286.41. Following the sale, the insider now directly owns 120,784 shares in the company, valued at approximately $4,419,486.56. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director W Don Cornwell sold 1,758 shares of Pfizer stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total value of $64,676.82. Following the completion of the sale, the director now owns 1,000 shares in the company, valued at $36,790. The disclosure for this sale can be found here. Over the last quarter, insiders sold 248,037 shares of company stock worth $9,064,785. Corporate insiders own 0.06% of the company’s stock.
Shares of Pfizer stock opened at $36.78 on Monday. The firm has a market capitalization of $218,946.38, a P/E ratio of 10.48, a PEG ratio of 2.07 and a beta of 0.91. Pfizer Inc. has a 1 year low of $31.67 and a 1 year high of $39.43. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the company earned $0.47 EPS. equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer announced that its Board of Directors has authorized a share buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/19/pfizer-inc-pfe-is-community-financial-services-group-llcs-9th-largest-position.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.